// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Dysregulated Myocardial Calcium Handling is a Driver of Early Heart Failure in Type 1 and Type 2 Diabetes

Shruti S Joshi - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Prevalence and Correlates of Echocardiographic Abnormalities in Type 2 Diabetes Insights From iCaReMe Global Registry

Mikhail N Kosiborod - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Chronic kidney disease

N/A

Cardiometabolic Disease Protein Signatures and Response to GLP-1 Receptor Agonist in the EXSCEL Clinical Trial

Rachel Ostroff - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Exenatide

Type 2 Diabetes and Atrial Fibrillation Exploring Causal Pathways Using Mendelian Randomization

Maddalena Ardissino - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Weight Loss Improves Cardiometabolic Health as Measured by Plasma Proteins in Individuals With Type 2 Diabetes

Naveed Sattar - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Adipose Tissue Derived Ceramides Regulate the Myocardial Redox State and Predict Cardiovascular Outcomes

Murray D Polkinghorne - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Initial Bilateral Pulmonary Artery Banding for Infants With Critical Left Heart Obstruction A Multi-Institutional Analysis of Outcomes

Madison B Argo - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Post-Operative Dialysis in Failing Fontan Patients Undergoing Heart Transplant How Well Does the Pre-Transplant Creatinine Clearance Risk-Stratify Patients?

Humera Ahmed - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Fontan failure

N/A

International Multicenter Registry Study of Patients With Variants in ATP1A3-Encoded Sodium-Potassium ATPase 3 Finds an Association With Short QT and Life-Threatening Ventricular Arrhythmias

Mary E Moya-Mendez - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Ventricular arrhythmias

N/A

Pediatric Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)

Sarah Abou Alaiwi - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertrophic cardiomyopathy

N/A

Sex Differences and Disparities in Cardiovascular Outcomes of Covid-19

Maria Bergami - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute respiratory failure

N/A

Gender Differences in the Relationship Between Health Rating and Disruption of Medical Care in Atherosclerotic Disease Populations Due to COVID-19

Onoriode Kesiena - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Does Social Disadvantage Modify the Association Between Health Rating and Disruption Due to COVID-19 Among Adults With Hypertension

Onoriode Kesiena - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

N/A

Detection and Characterization of Fibrin/Amyloid Microclots in Patients With Post-Acute Sequelae of Covid-19

Melanie Walker - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Trypsin

Utility of a Proteomic Surrogate for Cardiovascular Outcomes to Predict and Monitor COVID-19 Induced Myocarditis

Clare Paterson - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Viral myocarditis

N/A

Cardiopulmonary Assessment of COVID-19 Survivors Stratified by Acute Disease Severity and Post-Acute Symptoms

Yishay Szekely - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Orally Inhaled Flecainide for the Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm Final Results From the Phase 2 Instant Trial

Alan J Camm - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Flecainide

Steerable versus Non-Steerable Sheath Technology in Atrial Fibrillation Ablation A Systematic Review and Meta-Analysis

Mohammed Mhanna - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Atrioventricular Junctional Ablation in Patients With Atrial Fibrillation With and Without Heart Failure A Meta-Analysis

Christian Lewinter - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Patient-Reported Treatment Satisfaction in Etripamil-Mediated Conversion of Supraventricular Tachycardia to Sinus Rhythm Results From the NODE-301 Study

James E Ip - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Etripamil

Copyright © 2026. QuantiNova All rights reserved